Last, Lambertini et al. recently published data from the NeoALTTO trial where patients with HER2-positive early breast cancer were treated with neo-adjuvant anti-HER2 therapy alone (trastuzumab and/or lapatinib) for 2 cycles (6 weeks total) and then together with weekly paclitaxel for 12 cycles. Here, ERBB2 is linked to breast cancer.